BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25760976)

  • 1. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
    Chacón M; Eleta M; Espindola AR; Roca E; Méndez G; Rojo S; Pupareli C
    Future Oncol; 2015; 11(6):953-64. PubMed ID: 25760976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
    Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
    Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
    Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
    Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
    Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
    Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
    Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
    J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
    Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
    Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Evaluation of Response Using
    Farag S; Geus-Oei LF; van der Graaf WT; van Coevorden F; Grunhagen D; Reyners AKL; Boonstra PA; Desar I; Gelderblom H; Steeghs N
    J Nucl Med; 2018 Feb; 59(2):194-196. PubMed ID: 28970330
    [No Abstract]   [Full Text] [Related]  

  • 18. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor.
    Basu S; Mohandas KM; Peshwe H; Asopa R; Vyawahare M
    Nucl Med Commun; 2008 Dec; 29(12):1026-39. PubMed ID: 18987522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Shinto A; Nair N; Dutt A; Baghel NS
    Clin Nucl Med; 2008 Jul; 33(7):486-7. PubMed ID: 18580237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging features of bone metastases in patients with gastrointestinal stromal tumors.
    Jati A; Tatlı S; Morgan JA; Glickman JN; Demetri GD; Van den Abbele A; Silverman SG
    Diagn Interv Radiol; 2012; 18(4):391-6. PubMed ID: 22407696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.